Changes in expression of the albumin, fibronectin and type I procollagen genes in CCl4-induced liver fibrosis: Effect of pyridoxol L,2-pyrrolidon-5 carboxylate

B. Arosio, D. Santambrogio, N. Galgiano, G. Annoni

Research output: Contribution to journalArticle

Abstract

The protective activity of pyridoxol L,2-pyrrolidon-5 carboxylate (metadoxine) was investigated in a rat model of carbon tetrachloride (CCL4)-induced hepatic fibrosis. After 6 weeks of CCl4 treatment, the animals developed fibrosis and inflammation of the liver while those treated with CCl4+metadoxine had less severe lesions (P <0.05). Since in liver fibroplasia there are quantitative changes of the extracellular matrix components and almost invariably a decrease in albumin synthesis, we have also investigated by Northern blot analysis the expression of the cellular fibronectin, pro-alpha2(I)collagen and albumin genes. There were striking increases in fibronectin and pro-alpha2(I)collagen mRNA contents in the livers of CCL4-treated animals and these enhancements were less evident in the metadoxine-treated rats. In contrast, albumin mRNA levels, almost identical in control and metadoxine-treated rats, were lower in the CCl4-treated animals. These data suggest that metadoxine might slow the development of CCl4-mediated liver fibrosis.

Original languageEnglish
Pages (from-to)301-304
Number of pages4
JournalPharmacology and Toxicology
Volume73
Issue number6
Publication statusPublished - 1993

Fingerprint

Pyridoxine
Collagen Type I
Fibronectins
Liver Cirrhosis
Liver
Albumins
Genes
Rats
Animals
Messenger RNA
Carbon Tetrachloride
Northern Blotting
Extracellular Matrix
Fibrosis
metadoxine
Inflammation

ASJC Scopus subject areas

  • Health, Toxicology and Mutagenesis
  • Pharmacology
  • Toxicology

Cite this

Changes in expression of the albumin, fibronectin and type I procollagen genes in CCl4-induced liver fibrosis : Effect of pyridoxol L,2-pyrrolidon-5 carboxylate. / Arosio, B.; Santambrogio, D.; Galgiano, N.; Annoni, G.

In: Pharmacology and Toxicology, Vol. 73, No. 6, 1993, p. 301-304.

Research output: Contribution to journalArticle

@article{a0b6480f152746f2832c682b5325807e,
title = "Changes in expression of the albumin, fibronectin and type I procollagen genes in CCl4-induced liver fibrosis: Effect of pyridoxol L,2-pyrrolidon-5 carboxylate",
abstract = "The protective activity of pyridoxol L,2-pyrrolidon-5 carboxylate (metadoxine) was investigated in a rat model of carbon tetrachloride (CCL4)-induced hepatic fibrosis. After 6 weeks of CCl4 treatment, the animals developed fibrosis and inflammation of the liver while those treated with CCl4+metadoxine had less severe lesions (P <0.05). Since in liver fibroplasia there are quantitative changes of the extracellular matrix components and almost invariably a decrease in albumin synthesis, we have also investigated by Northern blot analysis the expression of the cellular fibronectin, pro-alpha2(I)collagen and albumin genes. There were striking increases in fibronectin and pro-alpha2(I)collagen mRNA contents in the livers of CCL4-treated animals and these enhancements were less evident in the metadoxine-treated rats. In contrast, albumin mRNA levels, almost identical in control and metadoxine-treated rats, were lower in the CCl4-treated animals. These data suggest that metadoxine might slow the development of CCl4-mediated liver fibrosis.",
author = "B. Arosio and D. Santambrogio and N. Galgiano and G. Annoni",
year = "1993",
language = "English",
volume = "73",
pages = "301--304",
journal = "Pharmacology and Toxicology",
issn = "0901-9928",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Changes in expression of the albumin, fibronectin and type I procollagen genes in CCl4-induced liver fibrosis

T2 - Effect of pyridoxol L,2-pyrrolidon-5 carboxylate

AU - Arosio, B.

AU - Santambrogio, D.

AU - Galgiano, N.

AU - Annoni, G.

PY - 1993

Y1 - 1993

N2 - The protective activity of pyridoxol L,2-pyrrolidon-5 carboxylate (metadoxine) was investigated in a rat model of carbon tetrachloride (CCL4)-induced hepatic fibrosis. After 6 weeks of CCl4 treatment, the animals developed fibrosis and inflammation of the liver while those treated with CCl4+metadoxine had less severe lesions (P <0.05). Since in liver fibroplasia there are quantitative changes of the extracellular matrix components and almost invariably a decrease in albumin synthesis, we have also investigated by Northern blot analysis the expression of the cellular fibronectin, pro-alpha2(I)collagen and albumin genes. There were striking increases in fibronectin and pro-alpha2(I)collagen mRNA contents in the livers of CCL4-treated animals and these enhancements were less evident in the metadoxine-treated rats. In contrast, albumin mRNA levels, almost identical in control and metadoxine-treated rats, were lower in the CCl4-treated animals. These data suggest that metadoxine might slow the development of CCl4-mediated liver fibrosis.

AB - The protective activity of pyridoxol L,2-pyrrolidon-5 carboxylate (metadoxine) was investigated in a rat model of carbon tetrachloride (CCL4)-induced hepatic fibrosis. After 6 weeks of CCl4 treatment, the animals developed fibrosis and inflammation of the liver while those treated with CCl4+metadoxine had less severe lesions (P <0.05). Since in liver fibroplasia there are quantitative changes of the extracellular matrix components and almost invariably a decrease in albumin synthesis, we have also investigated by Northern blot analysis the expression of the cellular fibronectin, pro-alpha2(I)collagen and albumin genes. There were striking increases in fibronectin and pro-alpha2(I)collagen mRNA contents in the livers of CCL4-treated animals and these enhancements were less evident in the metadoxine-treated rats. In contrast, albumin mRNA levels, almost identical in control and metadoxine-treated rats, were lower in the CCl4-treated animals. These data suggest that metadoxine might slow the development of CCl4-mediated liver fibrosis.

UR - http://www.scopus.com/inward/record.url?scp=0027763593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027763593&partnerID=8YFLogxK

M3 - Article

C2 - 7512265

AN - SCOPUS:0027763593

VL - 73

SP - 301

EP - 304

JO - Pharmacology and Toxicology

JF - Pharmacology and Toxicology

SN - 0901-9928

IS - 6

ER -